CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii

Area of Science:

• Parasitology
• Drug Discovery
• Structural Biology

Background:

• Toxoplasma gondii causes severe disease, especially in immunocompromised individuals and neonates.
• Current treatments for toxoplasmosis lack efficacy against the bradyzoite stage.
• Urgent need for novel therapeutic strategies against toxoplasmosis.

Purpose of the Study:

• Identify and characterize potential therapeutic targets for toxoplasmosis.
• Evaluate the druggability and therapeutic potential of identified targets.
• Assess the efficacy of targeting specific parasitic enzymes in vitro and in vivo.

Main Methods:

• Utilized databases, crystallography, and molecular modeling to identify drug targets.
• Structurally characterized key parasitic enzymes: PGMII, NDK, RPE, RPI, and OAT.
• Employed antisense technology (vivoPMO) to inhibit enzyme synthesis and assess parasitic replication.

Main Results:

• Structural analysis provided insights into enzyme active sites and ligand interactions.
• vivoPMO targeting demonstrated significant inhibition of parasite replication with no host cell toxicity.
• PGM, RPE, and RPI were identified as crucial for tachyzoite replication and parasite fitness.
• Identified targets are conserved across other medically relevant parasites.

Conclusions:

• PGM, RPE, and RPI represent promising therapeutic targets for toxoplasmosis.
• Targeted inhibition of these enzymes offers a potential treatment strategy with high specificity.
• The identified targets may hold broader therapeutic applications for other parasitic infections.